MedPath

Probiotics in the Treatment of Irritable Bowel Syndrome

Phase 2
Completed
Conditions
Irritable Bowel Syndrome
Interventions
Drug: Placebo
Registration Number
NCT01837472
Lead Sponsor
Isfahan University of Medical Sciences
Brief Summary

Evidence have shown benefits of gut flora modulation in treatment of irritable bowel syndrome (IBS), but few reports are available on the effects of multistrain probiotics and there are few reports available in this regard from our society. Thus, we investigated if probiotics are effective in our patients as well. We hypothesize that the multistrain probiotic Balance containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains, and Streptococcus thermophiles reduces the symptoms of irritable bowel syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
132
Inclusion Criteria
  • age between 18 and 65
  • diagnosis of IBS based on the Rome III criteria
  • willingness to participate
Exclusion Criteria
  • receiving other probiotics compound during the study
  • receiving antibiotics during the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
ProbioticProbiotic-
Primary Outcome Measures
NameTimeMethod
Abdominal painUp to 6 weeks

Abdominal pain was assessed by Rome III questionnaire at baseline and then after 6 weeks

Secondary Outcome Measures
NameTimeMethod
Quality of LifeUp to 6 weeks

Quality of life was assessed by the IBS-QOL questionnaire at baseline and then after 6 weeks.

Trial Locations

Locations (1)

Department of Gastroenterology, Alzahra Hospital

🇮🇷

Isfahan, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath